Institutional Repository of Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
| Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging | |
Liang, Qian1,2,3 ; Kong, Lingxin1,2,3; Du, Yang1,2,3; Zhu, Xu4; Tian, Jie1,2,3,5,6
| |
| Source Publication | EXPERIMENTAL AND MOLECULAR MEDICINE
 |
| ISSN | 1226-3613 |
| 2019-07-08 | |
| Volume | 51Pages:11 |
| Corresponding Author | Du, Yang(yang.du@ia.ac.cn) ; Zhu, Xu(drzhuxu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn) |
| Abstract | Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Sorafenib is the standard first-line treatment for advanced HCC, but its efficacy is limited. Apatinib is a small-molecule tyrosine kinas e inhibitor that has shown promising antitumor effects in gastric and non-small cell lung cancers in clinical trials, but there have been only a few studies reporting its anti-HCC effects in vitro and in HCC xenograft models. Hence, our present study systemically investigated and compared the antitumorigenic and antiangiogenic efficacy of apatinib and sorafenib in HCC in vitro and in vivo using multimodality molecular imaging, including bioluminescence imaging (BLI), bioluminescence tomography (BLT), fluorescence molecular imaging (FMI), and computed tomography angiography ( CTA). Moreover, the safety and side effects of the two drugs were systemically evaluated. We found that apatinib showed a comparable therapeutic efficacy to sorafenib for the inhibition of HCC. The drug safety evaluation revealed that both of these drugs caused hypertension and mild liver and kidney damage. Sorafenib caused diarrhea, rash, and weight loss in mice, but these effects were not observed in mice treated with apatinib. In conclusion, apatinib has similar antitumorigenic and antiangiogenic efficacy as sorafenib in HCC with less toxicity. These findings may provide preclinical evidence supporting the potential application of apatinib for the treatment of HCC patients. |
| DOI | 10.1038/s12276-019-0274-7 |
| WOS Keyword | HEPATOCELLULAR-CARCINOMA ; THERAPY ; ANGIOGENESIS ; TOMOGRAPHY ; MODELS ; TUMORS |
| Indexed By | SCI |
| Language | 英语 |
| Funding Project | National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022] ; National Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022] |
| Funding Organization | National Key Research and Development Plan of China ; National Natural Science Foundation of China ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science and Technology Commission |
| WOS Research Area | Biochemistry & Molecular Biology ; Research & Experimental Medicine |
| WOS Subject | Biochemistry & Molecular Biology ; Medicine, Research & Experimental |
| WOS ID | WOS:000474511300002 |
| Publisher | NATURE PUBLISHING GROUP |
| Sub direction classification | 其他 |
| Citation statistics | |
| Document Type | 期刊论文 |
| Identifier | http://ir.ia.ac.cn/handle/173211/26901 |
| Collection | 中国科学院分子影像重点实验室 |
| Corresponding Author | Du, Yang; Zhu, Xu; Tian, Jie |
| Affiliation | 1.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Beijing 100190, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100080, Peoples R China 3.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China 4.Peking Univ, Dept Intervent Therapy, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Sch Oncol, 52 Fucheng Rd, Beijing 100142, Peoples R China 5.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med, Beijing 100191, Peoples R China 6.Xidian Univ, Engn Res Ctr Mol & Neuro Imaging, Sch Life Sci & Technol, Minist Educ, Xian 710126, Shaanxi, Peoples R China |
| First Author Affilication | Institute of Automation, Chinese Academy of Sciences; Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China |
| Corresponding Author Affilication | Institute of Automation, Chinese Academy of Sciences; Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China |
| Recommended Citation GB/T 7714 | Liang, Qian,Kong, Lingxin,Du, Yang,et al. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging[J]. EXPERIMENTAL AND MOLECULAR MEDICINE,2019,51:11. |
| APA | Liang, Qian,Kong, Lingxin,Du, Yang,Zhu, Xu,&Tian, Jie.(2019).Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.EXPERIMENTAL AND MOLECULAR MEDICINE,51,11. |
| MLA | Liang, Qian,et al."Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging".EXPERIMENTAL AND MOLECULAR MEDICINE 51(2019):11. |
| Files in This Item: | Download All | |||||
| File Name/Size | DocType | Version | Access | License | ||
| s12276-019-0274-7.pd（2847KB） | 期刊论文 | 作者接受稿 | 开放获取 | CC BY-NC-SA | View Download | |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment